Skip to main content
SpringerLink
Log in

The history of cyclosporin A (Sandimmune®) revisited: Another point of view

  • Reviews
  • Published:
Experientia Aims and scope Submit manuscript

Abstract

The immunosuppressant cyclosporin A (Sandimmune®) has become the first line treatment for preventing rejection of transplanted organs and for certain, autoimmune diseases. The discovery of that drug and its preclinical development are described, and it is shown that most earlier accounts of the history of this compound are, in important respects, incorrect and misleading.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Literatur

  1. Aldridge, D. C., Armstrong, J. J., Speake, R. N., and Turner, W. B., The cytochalasins, a new class of biologically active mould metabolites. Chem. Commun. (1967) 26–27.

  2. Arrenbrecht, S., and Lazary, S., Effect of the immunosuppressive agent ovalicin on the kinetics of antibody formation. Agents and Actions1 (1970) 221–226.

    Article  CAS  PubMed  Google Scholar 

  3. Bäumler, E.: Die grossen Medikamente. Lübbe, Bergisch Gladbach 1992.

  4. Bernard, J., Ciclosporin: Foreword. Prog. Allergy38 (1986) 1–8.

    CAS  PubMed  Google Scholar 

  5. Bollinger, P., Sigg, H. P., and Weber, H. P., Die Struktur von Ovalicin. Hely. chim. Acta56 (1973) 819–830.

    Article  CAS  Google Scholar 

  6. Borel, J. F., Comparative study of in vitro and in vivo drug effects on cell-mediated cytotoxicity. Immunology31 (1976) 631–641.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Borel, J. F., The history of cyclosporin A and its significance, in: Cyclosporin A, pp. 5–17. Ed. D. J. G. White. Elsevier, Oxford 1982.

    Google Scholar 

  8. Borel, J. F., Address at the presentation of the Prix Galien of France, published in Press Folder of Sandoz Basel, May 1984.

  9. Borel, J. F., Interview published in the brochure “Sandimmune” of Laboratories Sandoz, France, 1984.

    Google Scholar 

  10. Borel, J. F., Feurer, C., Gubler, H. U., and Stähelin, H., Biological effects of cyclosporin A: a new antilymphocytic agent. Agents and Actions6 (1976) 468–475.

    Article  CAS  PubMed  Google Scholar 

  11. Borel, J. F., Feurer, C., Magnée, C., and Stähelin, H., Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology32 (1977) 1017–1025.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Borel, J. F., Kis, Z. L., The discovery and development of cyclosporine (Sandimmune). Transplant. Proc.23 (1991) 1867–1874.

    CAS  PubMed  Google Scholar 

  13. Borel, J. F., Rüegger, A., and Stähelin, H., Cyclosporin A: a new antilymphocytic agent. Experientia32 (1976) 777.

    Google Scholar 

  14. Bridel, F., Ces médicaments qui ont changé la vie. Chapitre 3, pp. 26–38. Payot, Lausanne 1985.

    Google Scholar 

  15. Bueding, E., Hawkins, J. and Cha, Y.-N., Antischistosomal effects of cyclosporin A. Agents and Actions11 (1981) 380–383.

    Article  CAS  PubMed  Google Scholar 

  16. Calne, R. Y., The development of immunosuppression in organ transplantation. Progr. Transplant.1 (1984) 1–10.

    Google Scholar 

  17. Calne, R. Y., and White, D. J. G., cyclosporin A — a powerful immunosuppressant in dogs with renal allografts. IRCS med. Sci.5 (1977) 595.

    CAS  Google Scholar 

  18. Calne, R. Y., White, D. J. G., Rolles, K., Smith, D. P., and Herbertson, B. M., Prolonged survival of pig orthotopic heart grafts treated with cyclosporin A. LancetI (1978) 1183–1185.

    Article  Google Scholar 

  19. Calne, R. Y., White, D. J. G., Thiru, S., Evans, D. B., McMaster, P., Dunn, D. C., Craddock, G. N., Pentlow, D. B., and Rolles, K., Cyclosporin A in patients receiving renal allografts from cadaver donors. LancetII (1978) 1323–1327.

    Article  Google Scholar 

  20. Carter, S. B., Effects of cytochalasins on mammalian cells. Nature, Lond.213 (1967) 261–264.

    Article  CAS  PubMed  Google Scholar 

  21. Closse, A., und Huguenin, R., Isolierung und Strukturaufklärung von Chlamydocin. Helv. chim. Acta57 (1974) 533–545.

    Article  CAS  PubMed  Google Scholar 

  22. Dawkins, A. W., Grove, J. F., and Tidd, B. K., Diacetoxyscirpenol and some related compounds. Chem. Commun. (1965) 27–28.

  23. DeSimone, P. A., Greco, F. A., Lessner, H. F., and Bartolucci, A., Phase II evaluation of anguidine (NSC 141537) in 5-day courses in colorectal adenocarcinoma. A Southeastern Cancer Study Group trial. Am. J. clin. Oncol.9 (1986) 187–188.

    Article  CAS  PubMed  Google Scholar 

  24. Doyle, T. W., and Bradner, W. T., Trichothecanes, in: Anticancer agents based on natural product models, pp. 43–72. Eds J. M. Cassady and J. D. Douros. Academic Press, New York 1980.

    Google Scholar 

  25. Dreyfuss, M., Neue Erkenntnisse aus dem pharmakologischen Pilz-Screening. Sydowia39 (1986) 22–36.

    Google Scholar 

  26. Dreyfuss, M., and Chapela, I. H., Potential of fungi in the discovery of novel, low-molecular weight pharmaceuticals, in: The Discovery of Natural Products with Therapeutic Potential, pp. 49–80. Ed. V. P. Gullo. Butterworth-Heinemann, Boston 1994.

    Chapter  Google Scholar 

  27. Dreyfuss, M., Härri, E., Hofmann, H., Kobel, H., Pache, W., and Tscherter, H., Cyclosporin A and C. New metabolites fromTrichoderma polysporum (Link ex pers.) Rifai. Europ. J. appl. Microbiol.3 (1976) 125–133.

    CAS  Google Scholar 

  28. Editorial, Cyclosporin turns five. Science242 (1988) 198.

  29. Flury, E., Mauli, R., and Sigg, H. P., The constitution of diacetoxyscirpenol. Chem. Commun. (1965) 26–27.

  30. Gorner, P., Wonderworker. Chicago Tribune, Dec. 28, 1988.

  31. Green, C. J., and Allison, A. C., Extensive prolongation of rabbit kidney allograft survival after short-term cyclosporin-A treatment. The LancetI (1978) 1182–1183.

    Article  Google Scholar 

  32. Gutzwiller, J., and Tamm, C., Ueber die Struktur von Verrucarin A. Helv. chim. Acta48 (1965) 157–176.

    Article  CAS  PubMed  Google Scholar 

  33. Haller, M., Der Sandimmun-Krimi: Die Geschichte des Medikamentes, mit dem heute am meisten Geld verdient wird. Weltwoche (Zürich) Dec. 3 (1992) 61–63; Dec. 10 (1992) 53; Dec. 17 (1992) 47. An English translation by F. Niklaus is available from the author of the present paper.

  34. Härri, E., Loeffler W., Sigg, H. P. Stähelin, H., Stoll, Ch., Tamm, Ch., and Wiesinger, D., Ueber die Verrucarine und Roridine, eine Gruppe von cytostatisch hochwirksamen Antibiotica aus Myrothecium-Arten. Helv. chim. Acta45 (1962) 839–853.

    Article  Google Scholar 

  35. Härri, E., Loeffler W., Sigg, H. P., Stähelin, H., and Tamm, Ch., Ueber die Isolierung neuer Stoffwechselprodukte aus Penicillium brefeldianum Dodge. Helv. chim. Acta46 (1963) 1235–1243.

    Article  Google Scholar 

  36. Hartmann, G. R., Richter, H., Weiner, E. M., and Zimmermann, W., On the mechanism of action of the cytostatic drug anguidine and of the immunosuppressive agent ovalicin, two sesquiterpenes from fungi. Planta med.34 (1978) 231–252.

    Article  CAS  PubMed  Google Scholar 

  37. Hofmann, A., Planung und Zufall in der pharmazeutischchemisschen Forschung. Sandoz Bulletin50 (1979) 4–17.

    Google Scholar 

  38. Kolata, G., Drug transforms transplant medicine (Editorial). Science221 (1983) 40–42.

    Article  CAS  PubMed  Google Scholar 

  39. Kostakis, A. J., White, D. J. G., and Calne, R. Y., Prolongation of the rat heart allograft survival by cyclosporin A. IRCS med. Sci.5 (1977) 280.

    CAS  Google Scholar 

  40. Lazary S., and Stähelin, H., Immunosuppressive, Wirkung von Podophyllumstoffen und andern Cytostatica, in: Proc. 5th Internat. Congr. Chemotherapy, (Vienna), pp. 317–322. Eds K. H. Spitzy and H. Haschek. Wiener mediz. Akademie. Wien 1967.

    Google Scholar 

  41. Lazary, S., and Stähelin, H., Immunosuppressive and specific antimitotic effects of ovalicin. Experientia24 (1968) 1171–1173.

    Article  CAS  PubMed  Google Scholar 

  42. Lazary, S., and Stähelin, H., Immunosuppressive effect of a new antibiotic: ovalicin. Antibiotica et Chemother.15 (1969) 177–181.

    Article  CAS  Google Scholar 

  43. Lazary, S., and Stähelin, H., Ovalicin and other drugs in experimental allergic encephalomyelitis (EAE). Experientia26 (1970) 691.

    Google Scholar 

  44. Mirocha, C. J., Pawlowsky, R. A., Chatterjee, K., Watson, S., and Hayes, W., Analysis of Fusarium toxins in various samples implicated in biological warfare in Southeast Asia. J. Ass. off. analyt. Chem.66 (1983) 1485–1499.

    CAS  Google Scholar 

  45. Misumi, Y., Misumi, Y., Miki, K., Takatsuki, A., Tamura, G., and Ikehara, Y., Novel blockade by brefeldin A of intracellular transport of secretory proteins in cultured rat hepatocytes. J. biol. Chem.261 (1986) 11398–11403.

    Article  CAS  PubMed  Google Scholar 

  46. Pestka, J. J., and Forsell, J. H., Inhibition of human lymphocyte transformation by the macrocyclic trichothecenes roridin A and verrucarin A. Toxic. Lett.41 (1988) 215–222.

    Article  CAS  Google Scholar 

  47. Petcher, T. J., Weber, H. P., and Rüegger., A., Crystal and molecular structure of an iodo-derivative of the cyclic undecapeptide cyclosporin A. Helv. chim. Acta59 (1976) 1480–1488.

    Article  CAS  PubMed  Google Scholar 

  48. Powles, R. L., Barrett, A. J., Clink, H., Kay, H. E. M., Sloane, J., and McElwain, T. J., Cyclosporin A for the treatment of graft-versus-host disease in man. LancetII (1978) 1327–1331.

    Article  Google Scholar 

  49. Re, R. N., Bioburst: The Impact of Modern Biology on the Affairs of Man. Louisiana State Univ. Press, Baton Rouge 1986.

    Google Scholar 

  50. Roberts, R. M., Serendipity. Wiley, New York 1989.

    Google Scholar 

  51. Rothweiler, W., and Tamm, Ch., Isolation and structure of phomin. Experientia22 (1966) 750–752.

    Article  CAS  Google Scholar 

  52. Rüegger, A., Kuhn, M., Lichti, H., Loosli, H. R., Huguenin, R., Quiquerez, C. and von Wartburg, A., Cyclosporin A, ein imunosuppressiv wirksamer, Peptidmetabolit ausTrichoderma polysporum (Link ex Pers.) Rifai. Helv. chim. Acta59 (1976) 1075–1092.

    Article  PubMed  Google Scholar 

  53. Rüsch, M. E., and Stähelin, H., Ueber einige biologische Wirkungen des Cytostaticum Verrucarin A. Arzneimittelforsch. (Drug Research)15 (1965) 893–897.

    PubMed  Google Scholar 

  54. Sawada, S., Suzuki, G., Kawase, Y., and Takaku, F., Novel immunosuppressive agent, FK 506. In vitro effects on the cloned T cell activation. J. Immun.139 (1987) 1797–1803.

    Article  CAS  PubMed  Google Scholar 

  55. Sigg, H. P., Die Konstitution von Brefeldin A. Helv. chim. Acta47 (1964) 1401–1415.

    Article  CAS  Google Scholar 

  56. Sigg, H. P., Mauli, R., Flury, E., and Hauser, D., Die Konstitution von Diacetoxyscirpenol. Helv. chim. Acta48 (1965) 962–988.

    Article  CAS  Google Scholar 

  57. Sigg, H. P., and Weber, H. P., Isolierung und Strukturaufklärung von Ovalicin. Helv. chim. Acta.51 (1968) 1395–1408.

    Article  CAS  PubMed  Google Scholar 

  58. de Souza, N. J., Ganguli, B. N., and Reden, J., Strategies in the discovery of drugs from natural sources. Ann. Rep. med. Chem17 (1982) 301–310.

    Google Scholar 

  59. Stähelin, H., Ueber osmotisches Verhalten und Fusion nackter Protoplasten von Bac. anthracis. Schweiz. Zs. allg. Path. Bakt.17 (1954) 296–310.

    Google Scholar 

  60. Stähelin, H., Internal Report, Sandoz Pharma of July 13, 1959, on compound No. 9648 (phomin, cytochalasin B).

  61. Stähelin, H., Internal Report Sandoz Pharma of October 6, 1960, on compound No. 11-247 (HPS 277, brefeldin A).

  62. Stähelin, H., A simple quantitative test for cytostatic agents using non-adhering cells in vitro. Med. exp.7 (1962) 92–102.

    PubMed  Google Scholar 

  63. Stähelin, H., Internal Report Sandoz Pharma of November 18, 1964, on compounds No. 7827 and 11-699/2.

  64. Stähelin, H., 4′-Demethyl-epipodophyllotoxin thenylidene glucoside (VM 26), a podophyllum compound with a new mechanism of action. Europ. J. Cancer6 (1970) 303–311.

    Article  Google Scholar 

  65. Stähelin, H., Ciclosporin: Historical background. Prog. Allergy38 (1986) 19–27.

    PubMed  Google Scholar 

  66. Stähelin, H., Enhanced toxicity of the immunosuppressant ovalicin upon application to the skin. Experientia44 (1988) 611–613.

    Article  PubMed  Google Scholar 

  67. Stähelin, H., The development of immunosuppressive agents from x-rays to cyclosporin, in: Immunology 1930–1980, Essays on the History of Immunology, pp. 185–201. Ed. P. M. H. Mazumdar. Wall and Thompson, Toronto 1989.

    Google Scholar 

  68. Stähelin, H., and Cerletti, A., Experimentelle Ergebnisse mit den Podophyllum-Cytostatica SP-I und SP-G. Schweiz. med. Wschr.94 (1964) 1490–1502.

    Google Scholar 

  69. Stähelin, H., Kalberer-Rüsch, M. E., Signer, E., und Lazary, S., Ueber einige biologische Wirkungen des Cytostaticum Diacetoxyscirpenol. Arzneimittelforsch. (Drug Research)18 (1968) 989–994.

    Google Scholar 

  70. Stähelin, H., Karnovsky, M. L., Farnham, A. E., and Suter, E., Studies on the interaction between phagocytes and tubercle bacilli. III. Some metabolic effects in guinea pigs associated with infection with tubercle bacilli. J. exp. Med.105 (1957) 265–277.

    PubMed  PubMed Central  Google Scholar 

  71. Stähelin, H., and Trippmacher, A., Cytostatic activity of chlamydocin, a rapidly inactivated cyclic tetrapeptide. Europ. J. Cancer10 (1974) 801–808.

    Article  Google Scholar 

  72. Stähelin, H., and von Wartburg, A. The chemical and biological route from podophyllotoxin glucoside to etoposide: ninth Cain Memorial Award Lecture. Cancer Res.51 (1991) 5–15.

    PubMed  Google Scholar 

  73. Tamm, Ch., The antibiotic complex of the verrucarins and roridins. Fortschr. Chem. Org. Naturst.31 (1974) 63–117.

    CAS  Google Scholar 

  74. Tamura, G., Ando, K., Suzuki, S., Takatsuki, A., and Arima, K., Antiviral activity of brefeldin A and verrucarin A. J. Antibiotic.21 (1968) 160–161.

    Article  CAS  Google Scholar 

  75. Thommen, K., Antimalarial activity of cyclosporin A. Agents and Actions11 (1981) 770–773.

    Article  Google Scholar 

  76. Thompson, L., Jean-François Borel's transplanted dream. Washington Post, November 15, 1988.

  77. Traxler, R., In der Pharma-Forschung beginnt die Zukunft in der Vergangenheit. Nordschweiz, September 23, 1988.

  78. Weiner, E., Ueber die immunosuppressive Wirkung des Sesquiterpens Ovalicin auf Lymphozyten. Thesis, Univ. of Würzburg 1976.

  79. White, D. J. G., and Calne, R. Y., The use of cyclosporin A immunosuppression in organ grafting. Immun. Rev.65 (1982) 115–131.

    Article  CAS  PubMed  Google Scholar 

  80. Wiederrecht, G., Lam E., Hung, S., Martin, M., and Sigal, N., The mechanism of action of FK-506 and cyclosporin A. Ann. N. Y. Acad. Sci.696 (1993) 9–19.

    Article  CAS  PubMed  Google Scholar 

  81. Wiskott, E., Sandimmun. Internat. Sandoz Gazette, March 1983.

  82. Woodruff, M., Concluding Remarks, in: Cyclosporin A, pp. 569–573. Ed. D. J. G. White. Elsevier, Oxford 1982.

    Google Scholar 

  83. van Ypersele de Strihou, C., La cyclosporine. J. Pharm. Belg.40 (1985) 109–112.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hardstrasse 80, CH-4052, Basel, Switzerland

    H. F. Stähelin

Authors
  1. H. F. Stähelin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stähelin, H.F. The history of cyclosporin A (Sandimmune®) revisited: Another point of view. Experientia 52, 5–13 (1996). https://doi.org/10.1007/BF01922409

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01922409

Key words

Search

Navigation